跳至主要内容
临床试验/NCT04231643
NCT04231643终止早期 1 期

A Randomized, Controlled Trial of Cannabis in Bipolar Disorder Patients and Healthy Volunteers Evaluating Cognition and Endocannabinoid Levels

University of California, San Diego1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2021年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
终止
入组人数
19
试验地点
1
主要终点
object interactions in the human Behavioral Pattern Monitor

研究概览

简要总结

Cannabis use is associated with younger age at onset of bipolar disorder, poor outcome, and more frequent manic episodes, but the effects of cannabis on cognition are less clear. Contrary to reports among non-psychiatric patients, cannabis may improve cognition among people with bipolar disorder. Nevertheless, no study to date has systematically tested the acute effects of cannabis on cognition in bipolar disorder. Therefore, the investigators propose to determine the effects of oral cannabinoid administration on cognitive domains relevant to bipolar disorder, e.g., arousal, decision making, cognitive control, inhibition, and temporal perception (sense of timing). In addition, the investigators will evaluate different doses of the two major components of cannabis, cannabidiol and ∆9-tetrahydrocannabinol, and compare them to placebo on these neurocognitive measures. The investigators will also test the effects of acute exposure to cannabinoids on cerebrospinal levels of anandamide and homovanillic acid - markers of endocannabinoid and dopamine activity in the brain, respectively. These studies will provide information that effectively bridges the fields of addiction and general psychiatry, informing treatment development for co-morbid substance abuse and psychiatric disorders.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • For subjects in BD group, DSM-5 criteria for Bipolar Disorder as determined by the Structured Clinical Interview for DSM-5 (SCID).
  • Young Mania Rating Scale (YMRS) <
  • Infrequent cannabis use as defined by a history of cannabis use and current use no more than 4 times per month.
  • Willing to abstain from cannabis use for at least two days prior to the experimental visit.

排除标准

  • Hamilton Depression Rating Scale (HDRS) score >
  • Suicidality. Exposure to cannabis does not lead to depression but it may be associated with suicidal thoughts and attempts. Therefore, the Center for Epidemiological Studies-Depression Scale (CES-D) subscale measuring suicidal ideation ("I wished I were dead". "I wanted to hurt myself") will be completed. Should any of these items be answered affirmatively, e.g., the subject has endorsed these items for at least 1-2 days in the last week, the subject will not be enrolled in the study.
  • The Substance Abuse Module of the Diagnostic Interview Schedule for DSM-5 will be administered to exclude individuals with current substance use disorders.
  • Clinically significant or unstable medical condition. Subjects will undergo a medical evaluation (H&P, toxicology screening, and for females of childbearing potential, pregnancy testing (utilizing a human chorionic gonadotropin (hCG) urine test). Individuals with significant cardiovascular disease (e.g., angina, myocardial infarction or stroke), hepatic or renal disease, uncontrolled hypertension, and chronic pulmonary disease (e.g., asthma, COPD), will be excluded. With respect to cardiovascular and pulmonary status, a clinician will screen participants with a tool developed for this purpose (Appendix 3 Cardiopulmonary Screen). Hepatic and renal disease will be evaluated with liver and renal function laboratory tests. Females who are pregnant or lactating will be excluded.
  • Infections - evidence of skin infection at lumbar puncture site.
  • To avoid confounding of cognitive testing, a neurological disorder such as seizures, stroke, Parkinson's disease, dementia, or a history of head injury with loss of consciousness for at least 15 minutes will be excluded.
  • Unwilling to refrain from driving or operate heavy machinery for four hours after consuming study medication. This criterion is consistent with current expert recommendations on driving following the use of cannabis.
  • Additionally, because the hBPM paradigm requires participants to be ambulatory, those who cannot ambulate independently (e.g., require a wheelchair) or those who have a motor disease (e.g., multiple sclerosis, cerebral palsy) will be excluded.
  • A previous adverse reaction to cannabinoids will be cause for exclusion as will a historical diagnosis of cannabis use disorder.
  • Positive result on Draeger 5000 test indicating recent cannabis use.
  • Unwillingness to prevent pregnancy during the cannabinoid administration portion of the study (using birth control in female participants of child-bearing age) Acceptable methods of birth control are: oral contraceptive pills, diaphragm, condom, progestin implant, intrauterine contraceptive device, sterilization, etc.
  • Any active opportunistic infection or malignant condition requiring acute treatment.

研究组 & 干预措施

Healthy Volunteers

Active Comparator

adults with no psychiatric disease

干预措施: Placebos (Drug)

Bipolar Disorder

Experimental

adults with bipolar disorder

干预措施: Dronabinol (Drug)

Bipolar Disorder

Experimental

adults with bipolar disorder

干预措施: Epidiolex (Drug)

Bipolar Disorder

Experimental

adults with bipolar disorder

干预措施: Placebos (Drug)

Healthy Volunteers

Active Comparator

adults with no psychiatric disease

干预措施: Dronabinol (Drug)

Healthy Volunteers

Active Comparator

adults with no psychiatric disease

干预措施: Epidiolex (Drug)

结局指标

主要结局

object interactions in the human Behavioral Pattern Monitor

时间窗: one day

This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via video ratings that quantify number of interactions with novel objects. Increased object interactions reflects increased novelty-seeking behavior.

Scores on Continuous Performance Task

时间窗: one day

This is an experimental measure and not a scale with specific anchor points. Higher scores reflect better attention and ability to discriminate important information from unimportant information

motor activity in the human Behavioral Pattern Monitor

时间窗: one day

This is an experimental measure and not a scale with specific anchor points. Subjects' behavior in an open field (a room filled with novel objects) is quantified over a 15-minute period via amount of motor activity as measured by a wearable accelerometer. Increased motor activity reflects increased tendency to engage in exploratory behavior.

Score on Iowa Gambling Task

时间窗: one day

This is an experimental measure and not a scale with specific anchor points. Lower scores reflect increased risk-taking

Scores on Probabilistic Learning Task

时间窗: one day

This is an experimental measure and not a scale with specific anchor points. Measures decision-making strategies such as win-stay, lose-shift.

cerebrospinal fluid levels of anandamide

时间窗: one day

Reflects increased availability of the endogenous cannabinoid anandamide in the brain

Score on Progressive Ratio Test

时间窗: one day

This is an experimental measure and not a scale with specific anchor points. Higher scores indicate increased willingness to work for a reward

Percent Prepulse Inhibition (PPI)

时间窗: one day

This is a physiological measure and not a scale with specific anchor points. Higher percent PPI reflects better sensorimotor gating

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

William Perry

Professor in Residence of Psychiatry

University of California, San Diego

研究点 (1)

Loading locations...

相似试验